Q2 2025 Financial Performance - Net sales decreased by 48% to $2096 million compared to Q2 2024[10, 22] - Adjusted operating income decreased by 209% to $228 million, with the adjusted operating income margin decreasing by 220 basis points to 109%[10, 22] - Adjusted net income decreased by 215% to $114 million, and diluted EPS decreased by 205% to $031[10] - The company generated strong free cash flow of $247 million, an increase of $148 million from the previous year[10] Segment Results - Material Handling net sales decreased by 44% to $1586 million, and adjusted operating income decreased by 109% to $289 million[31] - Distribution net sales decreased by 60% to $510 million, and adjusted operating income decreased by 444% to $16 million[33] Strategic Initiatives and Outlook - The company is launching a strategic review of Myers Tire Supply (MTS), which represents $189 million in sales over the last twelve months (LTM)[13] - The company is consolidating rotational molding production capacity by idling two of nine facilities, expecting at least $3 million in annual savings[15] - The company is tracking to achieve $20 million in cost savings by the end of 2025, primarily in SG&A[15, 41] - The company maintains a capital expenditure target of 3% of sales, focusing on high-growth opportunities[16, 39]

Financial Performance - Codere Online's Q2 2025 Net Gaming Revenue (NGR) reached €54.8 million, a 1% increase compared to Q2 2024, but a 12% increase at constant FX [28] - The company achieved a positive Adjusted EBITDA of €2.3 million in Q2 2025 [28] - Spain's NGR increased by 1% in Q2 2025, reaching €22.1 million [33, 48] - Mexico's NGR increased by 3% in Q2 2025 to €29 million, but increased 23% at constant currency [33, 55] Key Performance Indicators - Average Monthly Actives were approximately 155,000 in Q2 2025, a 7% increase compared to Q2 2024 [28] - The Average Monthly Spend per Active was €118, a 5% decrease compared to Q2 2024 [28] - Codere Online had approximately 277,000 new customer registrations with 78,000 First Time Deposits (FTDs) in Q2 2025, resulting in a 28% Conversion Rate [28] - The Cost per Acquisition (CPA) was €218 in Q2 2025 [28] Outlook - Codere Online projects a 2025 Net Gaming Revenue (NGR) between €220 million and €230 million [78] - The company anticipates an Adjusted EBITDA between €10 million and €15 million for 2025 [78]

Financial Performance - Q2 2025 total revenue reached $154.7 million, an 18% increase at CER (Constant Exchange Rates)[61] - Non-GAAP net income for Q2 2025 was $1.9 million[61] - The company expects to surpass $1 billion in total revenue in FY 2028[6] - The company reiterates FY 2025 total revenue growth guidance of 15% to 22% at CER[65,67] Product Performance - Galafold Q2 2025 revenue was $128.9 million, a 16% increase in reported sales growth[10] - The company anticipates Galafold revenue growth of 10% to 15% for FY 2025 at CER[4,65,67] - Pombiliti + Opfolda Q2 2025 revenue was $25.8 million, a 58% increase at CER[22] - The company anticipates Pombiliti + Opfolda revenue growth of 50% to 65% for FY 2025 at CER[5,25,65,67] Strategic Initiatives - The company acquired U S licensing of DMX-200 Phase 3 Program[4] - The company aims to deliver positive GAAP net income during H2 2025[65,67]

Whitestone REIT's Strategy & Performance - Whitestone focuses on acquiring high total return potential centers, anchoring them to the community, and constantly remerchandising to drive results via capital efficiency[4] - The company targets a Core FFO growth of 4-6%, matched by sustained dividend growth, underpinned by 3-5% Same Store NOI growth[11] - Whitestone aims to enhance Core FFO growth to 5-7% by adding accretive acquisitions with short-term lease up opportunities[11] - The company's strategy involves scaling the Whitestone model to reduce fixed costs and broaden the investor base[11] Financial Highlights & Metrics - Whitestone reported Q2 2025 revenue of $37.9 million, compared to $37.6 million in Q2 2024[8] - Core FFO per share was $0.26 in Q2 2025, up from $0.24 in Q2 2024[8] - Straight Line Leasing Spreads were 17.9% in Q2 2025, compared to 17.5% in Q2 2024[8] - The company's occupancy rate was 93.9% in Q2 2025, slightly up from 93.5% in Q2 2024[8] - Whitestone's Debt/EBITDAre ratio has improved to 7.1x, a 2.0x improvement versus 2021[8] Shop Space & Leasing - 77% of Whitestone's Total Annual Base Rent (ABR) is driven by small shop space tenants under 10,000 square feet[8, 32] - Whitestone's leasing spreads have shown strong performance, with Q2 2025 at 17.9%[5, 8] - The company forecasts a sustainable Same Store NOI growth of 3-5%, driven by contractual escalators (2.3%), leasing (0.8-1.8%), and redevelopment (up to 1.0%)[12, 13] Acquisitions & Dispositions - Whitestone has acquired approximately $153 million in property since Q4 2022, including S Hulen in Ft Worth and San Clemente in Austin in Q2 2025[26] - The company has completed approximately $126 million in dispositions since Q4 2022, including Woodlake in Houston in Q2 2025[26]

Restaurant Brands Asia Limited Investor Presentation July 31, 2025 Disclaimer Certain statements made in this presentation relating to the Company's objectives, projections, outlook, expectations, estimates, among others may constitute 'forward-looking statements' within the meaning of applicable laws and regulations. Actual results may differ from such expectations, projections etc., whether express or implied. These forward-looking statements are based on various assumptions, expectations and other factor ...

Financial Performance - Q3 2025 adjusted EPS was $3.09, a decrease of 3% compared to Q3 2024[14, 19] - Q3 2025 adjusted operating income was $741 million, flat compared to Q3 2024[14] - Q3 2025 adjusted operating income margin was 24.5%, flat compared to Q3 2024[14] - The company forecasts FY2025 capital expenditures to be approximately $5.0 billion[25] Sales Analysis - Overall sales increased by 1% compared to Q3 2024 and 4% compared to Q2 2025[16] - Volume decreased by 4% compared to Q3 2024 but increased by 4% compared to Q2 2025[16] - Sales in Americas increased 2% vs Q3FY24 but decreased 2% vs Q2FY25[33] - Sales in Asia increased 3% vs Q3FY24 and 5% vs Q2FY25[38] - Sales in Europe increased 11% vs Q3FY24 and 6% vs Q2FY25[43] Future Outlook - The company projects FY2025 adjusted EPS to be in the range of $11.90 to $12.10, a decrease of 4% to 3% compared to FY24[10, 25] - Q4 FY2025 adjusted EPS is projected to be between $3.27 and $3.47, representing an 8% to 3% decrease compared to Q4 FY24[25]

Q2 2025 Performance - Adjusted constant currency revenue grew by 1.0% year-over-year[12] - Adjusted gross margin was 59.7%[12] - Adjusted operating margin was 26.9%[12] - Adjusted EPS reached $3.73, a 9.1% increase year-over-year[12] 2025 Financial Guidance - Adjusted constant currency revenue growth guidance increased to a range of 7.70% to 8.70%, compared to the prior range of 1.00% to 2.00%[12] - Adjusted diluted EPS from continuing operations guidance increased to a range of $13.90 to $14.30, compared to the prior range of $13.20 to $13.60[12] - GAAP Revenue Growth is forecasted between 9.00% and 10.00%[41] Segment Performance (Q2 2025) - Americas reported revenue of $525.7 million, with adjusted constant currency revenue growth of 2.0%[13, 14] - EMEA reported revenue of $166.2 million, but experienced an adjusted constant currency revenue decline of 2.1%[13, 14] - Asia reported revenue of $89.0 million, with adjusted constant currency revenue growth of 1.2%[13, 14] Strategic Updates - Teleflex is progressing with the separation into RemainCo and NewCo, and is evaluating a potential sale of NewCo[23] - Teleflex completed the acquisition of BIOTRONIK's Vascular Intervention business for an initial upfront cash payment of €704 million[23]

Financial Performance - PYRUKYND net revenues reached $12.5 million in Q2 2025, a 44% increase compared to $8.7 million in Q1 2025 and a 45% increase compared to $8.6 million in Q2 2024[10] - The company maintains a strong financial position with $1.3 billion in cash on hand[9, 10, 14] - Net loss for Q2 2025 was $112.0 million, compared to a net loss of $96.1 million for Q2 2024[14] Pipeline Development - First patient dosed in Phase 2 Sickle Cell Disease trial for AG-236 after receiving IND clearance[11] - RISE UP Phase 3 trial in sickle cell disease is expected to have topline data by the end of 2025[37] - Tebapivat Phase 2b trial for LR-MDS is ongoing, with topline results expected in early 2026[9, 45] Commercialization - 248 unique PK deficiency patients completed prescription enrollment forms since launch in the U S [21] - 142 patients are on treatment in the U S , including new prescriptions and treatment continuations, with 215 unique prescribers[22] - The company anticipates a potential U S launch of PYRUKYND for thalassemia in Q3 2025, with a PDUFA goal date of September 7, 2025[11, 23, 24] Strategic Partnerships - Announced a commercialization and distribution partnership with Avanzanite Bioscience in Europe[10] - A commercialization and distribution agreement is in place with NewBridge for the GCC region, with anticipated first regulatory approval in the coming months[30]

Financial Performance & Guidance - CVS Health reported consolidated revenue growth of 8.4% in the second quarter of 2025[6] - Adjusted EPS for Q2 2025 was $1.81[6, 7, 11] - The company raised its 2025 adjusted EPS guidance to a range of $6.30 to $6.40[6, 14] - Full year 2025 consolidated revenue is projected to be at least $391.5 billion[7, 13] - Full year 2025 adjusted operating income is expected to be between $13.77 billion and $13.94 billion[7, 13] - Cash flow from operations for full year 2025 is projected to be at least $7.5 billion[7, 13] Segment Performance - Health Care Benefits total revenues for Q2 2025 were $36.3 billion[18] - Health Care Benefits adjusted operating income increased by nearly 40% year over year in Q2 2025[19] - Health Services total revenues for Q2 2025 were $46.5 billion[21] - Health Services adjusted operating income decreased ~18% year over year in Q2 2025[22] - Pharmacy & Consumer Wellness total revenues for Q2 2025 were $33.6 billion[24] - Pharmacy & Consumer Wellness adjusted operating income increased nearly 8% year over year in Q2 2025[25]

Financial Performance - Q2 2025 revenue reached €383 million, a 2% increase QoQ[8] - Q2 2025 gross margin was 378%[8] - Adjusted EBITDA loss for Q2 2025 was €75 million[8] - Q2 2025 cash costs decreased by 35% YoY[10] Sales and Product - Approximately 39000 AC units were sold in Q2 2025[10] - Approximately 140 DC units were sold globally in Q2 2025[10] - AC sales accounted for 69% of Q2 2025 revenue, DC sales for 11%, and Software, Services & Others for 20%[13] Geographical Revenue - Europe accounted for 68% of Q2 2025 revenue, with €261 million[11] - North America accounted for 30% of Q2 2025 revenue, with €114 million[11] - LATAM accounted for 1% of Q2 2025 revenue, with €550k[11] - APAC accounted for 1% of Q2 2025 revenue, with €260k[11]